NCT06001099 is a clinical trial in Gynecologic Cancer, sponsored by Fudan University.

Who is sponsoring NCT06001099?

NCT06001099 is sponsored by Fudan University.

What condition does NCT06001099 study?

NCT06001099 studies Gynecologic Cancer.

Is NCT06001099 still recruiting?

NCT06001099 is currently status unknown. Last updated 29 September 2023.

Last reviewed 2023-09-29 · How we verify

NCT06001099

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale Cancers, PERCEIVE-II

Status unknown Last updated 29 September 2023

What this trial tests

trial in Gynecologic Cancer in 2,935 participants. Status unknown.

Timeline

22 February 2023

Primary endpoint
30 June 2024

31 December 2024

Quick facts

Lead sponsor	Fudan University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	2,935
Start date	22 February 2023
Primary completion	30 June 2024
Estimated completion	31 December 2024
Sites	1 location across China

Conditions studied

Gynecologic Cancer — all drugs for Gynecologic Cancer →

Sponsor

Fudan University

Who can join

18 and older, female only, with Gynecologic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective study aimed to validate the performance of combined multi-omitcs assays for early detection of gynecologic cancers. Biomarkers of cfDNA methylation, ctDNA mutation and blood miRNA markers will be evaluated. The study will enroll approximately 2935 female participants, including participants with gynecologic cancers patients and healthy participants.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Exploring the clinical utility of liquid biopsy with cfDNA in cancer: A systematic review.
Ranganathan K, Kurian NS, Goswami HM, Rishi KD, et al · · 2024 · cited 5× · PMID 40027943 · DOI 10.1016/j.jlb.2024.100150
Targeting Regulatory Noncoding RNAs in Human Cancer: The State of the Art in Clinical Trials.
Piergentili R, Sechi S. · · 2025 · cited 2× · PMID 40284466 · DOI 10.3390/pharmaceutics17040471
Multicancer Early Detection Tests: A State-of-the-Art Review for Otolaryngologists.
Kennedy E, Durm G, Farlow JL. · · 2024 · cited 2× · PMID 39463807 · DOI 10.1002/oto2.70040

Verify or expand the search:

Other recruiting trials for Gynecologic Cancer

Currently open trials in the same condition.

NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07408349 — Guided Imagery of the Gynecological Cancer · NA · recruiting
NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting
NCT07173101 — Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on Cancer-related Cognitive Impairm · Phase 2 · recruiting
NCT07166042 — Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies · Phase 3 · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06001099 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 29 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06001099.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing